Sun Pharmaceutical Industries will look at strategic acquisitions, together with smaller “tuck-ins,” top-management mentioned, outlining technique, with out commenting on specifics being reported in the media.
The corporate will look at acquisitions provided that it helps strengthening long-term strategic alternative, Dilip Shanghvi, Sun Pharma’s Government Chairman instructed analysts, after it introduced its monetary efficiency for the third quarter ended December 31, 2025. The corporate will stay “disciplined” on acquisitions, he mentioned, and discover a method to develop organically. It will look at an acquisition “provided that it helps strengthening long-term strategic alternative,” he mentioned, including that they have been snug elevating debt.
The USA is vital to Sun’s modern merchandise enterprise, he mentioned, including that they have been looking to promote their modern merchandise in different international markets as nicely. The corporate would additionally look at “tuck-ins”or smaller acquisitions in emerging markets, he added.
Sun Pharma has just lately been reported as looking for a serious acquisition in the US, that will bolster its presence in girls’s well being. The corporate, nevertheless, referred to as the report “speculative,” in its response to the inventory exchanges.
The drugmaker clocked a 16 % progress in internet revenue at ₹3,368 crore, for the third quarter Q3, ended December 31, 2025. The corporate clocked a 15 % progress in gross sales at ₹15,469 crore, for the interval beneath evaluate. Its international modern medicines (specialty enterprise) stood at $423 million, together with a $55 million milestone cost. This was up 13.2 per cent accounting for 21.2 per cent of gross sales, ex-milestone, it mentioned.
Kirti Ganorkar, Sun Pharma’s Managing Director mentioned, that the corporate was looking to launch generic semaglutide on day one in every of patent expiry on the weight problems and diabetes drug.
On the efficiency in Q3, he mentioned, “Our outcomes this quarter show nicely‑rounded progress throughout all companies, prominently led by our branded companies in India, Emerging Markets and International Revolutionary Medicines. Our modern product providing has expanded additional with the launch of Unloxcyt in the US and the introduction of Ilumya in India.”
Printed on January 31, 2026
Source link
#Sun #Pharma #disciplined #acquisitions #tuckins #emerging #markets #Dilip #Shanghvi
